智通财经网·2025-12-15 05:55Core Viewpoint - JD Health is advancing its medical AI capabilities through the "Jingyi Qianxun" model, focusing on specialized disease models for cancer treatment and chronic diseases, collaborating with top medical institutions in China to enhance clinical practices and patient management [1][3][4]. Group 1: Technological Advancements - JD Health's "Jingyi Qianxun" medical AI model has evolved from a general model to specialized disease models, demonstrating significant technological progress since 2018 [4]. - The model integrates high-quality clinical data from JD's online healthcare services and collaborates with national medical data centers to optimize its foundational model [4][5]. - The specialized disease models are developed using real-world clinical data, ensuring alignment with actual clinical needs and incorporating insights from over 1,000 experts across more than 400 top-tier hospitals [5][6]. Group 2: Collaborative Initiatives - JD Health, in partnership with the China Anti-Cancer Association, launched the "Cancer Integration Prevention and Treatment Project (2025-2030)" to create a comprehensive cancer prevention and treatment system [3]. - Collaborations with leading hospitals, such as Peking University Cancer Hospital and Sun Yat-sen University Cancer Center, focus on developing specialized models for various cancer types, including gastrointestinal and respiratory cancers [5][6]. Group 3: AI Integration in Clinical Practice - The AI-driven tools, such as the AI doctor assistant, have improved the efficiency of oncologists, achieving over 90% resolution of repetitive queries and enhancing diagnostic processes by more than 50% [8]. - JD Health's research platform utilizes AI to streamline data collection and patient follow-up, significantly improving research efficiency and data quality for ongoing studies [8]. Group 4: Future Directions - JD Health aims to enhance its medical AI model towards human-like clinical cognition and will continue to foster open collaborations with medical institutions and experts [9]. - The company is committed to building a specialized cancer prevention and treatment system that ensures accessible resources, reliable decision-making, and effective patient management, contributing to the "Healthy China 2030" initiative [9].